This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is Cardinal Health (CAH) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: McKesson, Jabil and Halliburton
by Zacks Equity Research
McKesson, Jabil and Halliburton are part of the Zacks Investment Ideas article.
3 Highly-Ranked Stocks that Beat the Market in 2022 to Buy Now
by Benjamin Rains
Digging into three highly-ranked stocks that outperformed the market in 2022 amid the turmoil and are primed to keep running higher in 2023 even if Wall Street is forced to take its foot off the growth pedal.
Bruker (BRKR) Q4 Earnings Beat Estimates, Margins Increase
by Zacks Equity Research
Robust performance across most of the geographies and operating segments drove Bruker's (BRKR) Q4 revenues.
Phibro (PAHC) Q2 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Growing uptake of MFAs, dairy products and vaccines contributed to Phibro's (PAHC) Q2 revenues.
Cardiovascular Systems (CSII) Q2 Earnings, Revenues Miss
by Zacks Equity Research
With the announcement of the merger agreement with Abbott, Cardiovascular Systems (CSII) refrains from providing any update on the 2023 guidance.
DexCom (DXCM) Q4 Earnings Beat Estimates, Volumes Remain Strong
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Baxter (BAX) Q4 Earnings Miss Estimates, FY23 Outlook Weak
by Zacks Equity Research
Baxter's (BAX) fourth-quarter results reflect impact of additional sales from the legacy Hilrom's business acquired in 2021. Ongoing macroeconomic challenges hurt earnings significantly.
STERIS (STE) Q3 Earnings Miss Estimates, Margins Down Y/Y
by Zacks Equity Research
Negative foreign currency and the impact of increased supply chain and inflationary costs hurt STERIS (STE) revenues in the fiscal third quarter.
Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.
Illumina (ILMN) Q4 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Delays in recruitment for some large research projects in the Americas and Europe, the impact of COVID disruptions in China and foreign exchange woes hurt Illumina's (ILMN) Q4 revenues.
QIAGEN's (QGEN) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The ongoing double-digit sales growth in the non-COVID product portfolio contributed to QIAGEN's (QGEN) Q4 revenues.
CVS Health (CVS) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
CVS Health's (CVS) Retail/LTC segment revenues rise on increased prescription and front store volume, pharmacy drug mix and brand inflation.
Inspire Medical (INSP) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the fourth quarter.
Catalent (CTLT) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Catalent (CTLT) records lower revenues in both segments in its second-quarter fiscal 2023, resulting in overall soft performance.
Surmodics (SRDX) Q1 Earnings Top Estimates, FY23 View Revised
by Zacks Equity Research
Surmodics (SRDX) reports a solid fiscal first quarter top line on the back of robust Medical Device revenues.
Should Value Investors Buy AmerisourceBergen (ABC) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why McKesson (MCK) is Poised for a Turnaround After Losing -6.24% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for McKesson (MCK) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
IDEXX (IDXX) Q4 Earnings Beat Estimates, Margins Increases
by Zacks Equity Research
IDEXX's (IDXX) Q4 revenues are driven by continued benefits from expanding the global premium instrument installed base.
Avantor (AVTR) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Despite Avantor's (AVTR) robust core organic sales across its segments, it reports an overall soft Q4 performance.
Zacks Industry Outlook Highlights McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical
by Zacks Equity Research
McKesson, AmerisourceBergen, LabCorp, Cardinal Health and Merit Medical have been highlighted in this Industry Outlook article.
Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.
Is McKesson (MCK) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
McKesson (MCK) could produce exceptional returns because of its solid growth attributes.
CONMED (CNMD) Down on Q4 Earnings Miss, New System Hurts Sales
by Zacks Equity Research
CONMED's (CNMD) adjusted fourth-quarter sales and earnings reflect disruption due to implementation of a new warehouse management system.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.